RECRUITING: MirtaRett mirtazapine study – Italy
Posted: Thu Sep 03, 2026 10:47 pm
Status: RecruitingStudy: Repurposing mirtazapine in Rett syndrome (MirtaRett)
Registry number: NCT07430046
Country: Italy
Participants: Females aged 5–40 years
What is being studied?
This multicentre, open-label Phase 2 study is examining the safety and possible effects of mirtazapine on breathing, sleep, mood, movement and hand control. It is enrolling through Rett-specialist services in Genoa, Messina, Milan and Siena.
Contact: Prof. Enrico Tongiorgi — +39 348 73477322 — tongi@units.it
Official study record: https://clinicaltrials.gov/study/NCT07430046
Information checked 3 September 2026. Mirtazapine is being investigated for this use; effectiveness for Rett syndrome is not established. Contact the trial team and the person’s clinician before considering participation.
Registry number: NCT07430046
Country: Italy
Participants: Females aged 5–40 years
What is being studied?
This multicentre, open-label Phase 2 study is examining the safety and possible effects of mirtazapine on breathing, sleep, mood, movement and hand control. It is enrolling through Rett-specialist services in Genoa, Messina, Milan and Siena.
Contact: Prof. Enrico Tongiorgi — +39 348 73477322 — tongi@units.it
Official study record: https://clinicaltrials.gov/study/NCT07430046
Information checked 3 September 2026. Mirtazapine is being investigated for this use; effectiveness for Rett syndrome is not established. Contact the trial team and the person’s clinician before considering participation.